Back to today’s briefing

Story perspectives

Revolutionary Liquid Biopsy Initiative Launches in UAE

6/8/2025

42 9

Summary

Story summary

On June 7, 2025, M42, AstraZeneca, and SOPHiA GENETICS unveiled an innovative liquid biopsy initiative in the UAE, revolutionizing cancer diagnosis and treatment. This groundbreaking collaboration will focus on non-invasive genomic profiling for lung, ovarian, breast, colorectal, and pancreatic cancers, with validation studies kicking off at Cleveland Clinic Abu Dhabi.

1 of 1

Story summary

On June 7, 2025, M42, AstraZeneca, and SOPHiA GENETICS unveiled an innovative liquid biopsy initiative in the UAE, revolutionizing cancer diagnosis and treatment. This groundbreaking collaboration will focus on non-invasive genomic profiling for lung, ovarian, breast, colorectal, and pancreatic cancers, with validation studies kicking off at Cleveland Clinic Abu Dhabi.